Alvotech revenue

Alvotech's revenue was $586m in fiscal 2025, up 19.7% on the year before. Since fiscal 2020 ($66.6m) it has grown at a compound 54.5% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Alvotech: revenue history, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	67	37	83	91	490	586
Growth on the year before	—	−44.8%	+125.8%	+10.1%	+435.6%	+19.7%
Gross profit	—	37	19	−69	304	351
Gross margin	—	100.0%	22.8%	−75.9%	62.2%	59.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Alvotech	$586m	19.7%	—
Emergent Biosolutions Inc.	$649m	-17.7%	-16.2%
Travere Therapeutics, Inc.	$651m	49.4%	71.3%
Amphastar Pharmaceuticals, Inc.	$730m	1.0%	10.5%
Pacira Biosciences, Inc.	$746m	5.7%	3.7%
Innoviva, Inc.	$440m	18.8%	14.9%

Compare with peers

Head to head: ALVO vs EBS ALVO vs TVTX ALVO vs AMPH ALVO vs INVA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Alvotech's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alvotech.